1 | Abatacept Active Treatment | [1] Abatacept Abatacept | [1] D03203
D03203
| [2] CD80 CD80, CD86 💬 | [12] Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | [1] 50 50 |
2 | Abatacept Delayed-Onset Treatment | [1] Abatacept Abatacept | [1] D03203
D03203
| [2] CD80 CD80, CD86 💬 | [12] Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | [1] 50 50 |
3 | Active Investigational Treatment ENT-01 | - | - | - | - | [1] 6 6 |
4 | Active Treatment Group 7% Hypertonic Saline | - | - | - | - | [1] 299 299 |
5 | Background Treatment | - | - | - | - | [1] 46 46 |
6 | Baricitinib treatment | [1] Baricitinib Baricitinib | [1] D10308
D10308
| [2] JAK1 JAK1, JAK2 💬 | [35] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 46 46 |
7 | Baseline Treatment | - | - | - | - | [1] 13 13 |
8 | BDMARD treatment | - | - | - | - | [1] 271 271 |
9 | Behavioral: CO-OP treatment protocol | - | - | - | - | [1] 6 6 |
10 | Behavioral: conservative treatment | - | - | - | - | [1] 291 291 |
11 | Behavioral: Tobacco Treatment Specialist (TTS) intervention | [1] Tobacco leaf Tobacco leaf | - | - | - | [1] 299 299 |
12 | Best Medical Treatment | - | - | - | - | [1] 6 6 |
13 | Best médical treatment | - | - | - | - | [1] 6 6 |
14 | Bisphosphonate treatment | - | - | - | - | [2] 113 113, 299 |
15 | Botulism Toxin Treatment | - | - | - | - | [1] 161 161 |
16 | Break in L-carnitine treatment | [1] Levocarnitine Levocarnitine | [3] D02030
D02030
,
D02176
,
D04713
| - | - | [1] 316 316 |
17 | Chinese herbal medicine treatment | - | - | - | - | [1] 6 6 |
18 | Classic DMARDs treatment group | - | - | - | - | [1] 46 46 |
19 | Clobetasol Propionate cream treatment | [2] Clobetasol Clobetasol, Clobetasol propionate | [2] D01272
D01272
,
D07715
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 162 162 |
20 | Combination Product: Active treatment with dual therapy | - | - | - | - | [1] 2 2 |
21 | Corticosteroid treatment (Methylprednisolone or prednisolone) | [2] Methylprednisolone Methylprednisolone, Prednisolone | [14] D00407
D00407
,
D00472
,
D00751
,
D00979
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
,
D05000
,
D05001
,
D05002
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 64 64 |
22 | Crysvita (burosumab-twza) Treatment | [1] Burosumab Burosumab | [1] D10913
D10913
| [1] FGF23 FGF23 💬 | [11] Breast cancer Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬 | [1] 238 238 |
23 | Current lipid-lowering treatment | - | - | - | - | [1] 79 79 |
24 | Current treatment of AL-CM | - | - | - | - | [1] 28 28 |
25 | Detoxifying agents for antineoplastic treatment | - | - | - | - | [2] 299 299, 337 |
26 | Disease modifying treatment (DMT) | - | - | - | - | [1] 13 13 |
27 | Dopamine agonist treatment | [1] Dopamine Dopamine | [2] D00633
D00633
,
D07870
| [5] DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | [11] Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | [1] 74 74 |
28 | Drug treatment | - | - | - | - | [4] 46 46, 51, 74, 271 |
29 | ERA as specific PAH treatment | - | - | - | - | [1] 86 86 |
30 | Etanercept Treatment | [1] Etanercept Etanercept | [1] D00742
D00742
| [2] LTA LTA, TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 46 46 |
31 | Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 222 222 |
32 | Fibrate treatment | - | - | - | - | [1] 160 160 |
33 | Foliglurax 10 mg (treatment A) | [1] Foliglurax Foliglurax | - | - | - | [1] 6 6 |
34 | Foliglurax 30 mg (treatment B) | [1] Foliglurax Foliglurax | - | - | - | [1] 6 6 |
35 | From August 2020 'no additional treatment' | - | - | - | - | [1] 51 51 |
36 | GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made. | [1] Somatotropin Somatotropin | [1] D02691
D02691
| [1] GHR GHR 💬 | [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | [1] 193 193 |
37 | Glucocorticoid Treatment | - | - | - | - | [1] 41 41 |
38 | Golimumab treatment optimization. | [1] Golimumab Golimumab | [1] D04358
D04358
| [1] TNF TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 97 97 |
39 | HCQ/CQ and CAB combined treatment | - | - | - | - | [1] 74 74 |
40 | Herbal treatment (SA100) | - | - | - | - | [1] 97 97 |
41 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | [1] Xenon Xenon | [2] D01901
D01901
,
D06339
| - | - | [1] 85 85 |
42 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | [1] Xenon Xenon | [2] D01901
D01901
,
D06339
| - | - | [1] 85 85 |
43 | Immunosuppressive treatment | - | - | - | - | [1] 66 66 |
44 | Immunosuppressive treatment (eg, rituximab) | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 64 64 |
45 | In double-blind phase: treatment with tofacitinib | [1] Tofacitinib Tofacitinib | [1] D09970
D09970
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬 | [37] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 107 107 |
46 | In open-label phase: treatment with tofacitinib | [1] Tofacitinib Tofacitinib | [1] D09970
D09970
| [4] JAK1 JAK1, JAK2, JAK3, TYK2 💬 | [37] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | [1] 107 107 |
47 | Interferon beta treatment to add-on atorvastatin treatment | [2] Atorvastatin Atorvastatin, Human interferon beta | [3] D00258
D00258
,
D00887
,
D07474
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [1] 13 13 |
48 | IV treatment with IGSC, 10% | - | - | - | - | [1] 65 65 |
49 | Lapaquistat acetate and current lipid-lowering treatment | [2] Acetate Acetate, Lapaquistat | - | - | - | [1] 79 79 |
50 | Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | [5] Dapsone Dapsone, Mycophenolate mofetil, Mycophenolic acid, Prednisolone, Triamcinolone | [18] D00385
D00385
,
D00472
,
D00592
,
D00752
,
D00980
,
D00981
,
D00982
,
D00983
,
D00984
,
D00985
,
D01239
,
D01998
,
D02156
,
D03301
,
D05094
,
D05095
,
D05096
,
D06216
| [3] IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | [4] Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism 💬 | [1] 162 162 |
51 | Lumacaftor-Ivacaftor treatment | [2] Ivacaftor Ivacaftor, Lumacaftor | [2] D09916
D09916
,
D10134
| [1] CFTR CFTR 💬 | [8] ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | [1] 299 299 |
52 | Metformin treatment | [1] Metformin Metformin | [2] D00944
D00944
,
D04966
| [2] PRKAA1 PRKAA1, PRKAA2 💬 | [20] AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | [1] 46 46 |
53 | Methotrexate treatment | [1] Methotrexate Methotrexate | [2] D00142
D00142
,
D02115
| [2] DHFR DHFR, DHFR2 💬 | [5] Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | [2] 41 41, 46 |
54 | MK0812 / Duration of Treatment: 12 Weeks | - | - | - | - | [1] 46 46 |
55 | MSC treatment | - | - | - | - | [1] 49 49 |
56 | MSC treatment 01 | - | - | - | - | [1] 96 96 |
57 | MSC treatment 02 | - | - | - | - | [1] 96 96 |
58 | Natalizumab treatment | [1] Natalizumab Natalizumab | [1] D06886
D06886
| [1] ITGA4 ITGA4 💬 | [14] Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | [1] 13 13 |
59 | Nifurtimox-Eflronithine Combination Treatment (NECT) | [1] Nifurtimox Nifurtimox | [1] D00833
D00833
| - | - | [1] 65 65 |
60 | Nusinersen Treatments | [1] Nusinersen Nusinersen | [1] D10881
D10881
| [1] SMN2 SMN2 💬 | - | [1] 3 3 |
61 | OC oral solution treatment A | - | - | - | - | [1] 6 6 |
62 | OC oral solution treatment B | - | - | - | - | [1] 6 6 |
63 | OC oral solution treatment C | - | - | - | - | [1] 6 6 |
64 | OC oral solution treatment D | - | - | - | - | [1] 6 6 |
65 | Only 1 arm: treatment with MSC-AFP | - | - | - | - | [1] 96 96 |
66 | Optimized antiparkinsonian treatment | - | - | - | - | [1] 6 6 |
67 | Optimized oral treatment | - | - | - | - | [1] 6 6 |
68 | Oral anticoagulant treatment | - | - | - | - | [1] 86 86 |
69 | Other Parkinson's Disease treatments | - | - | - | - | [1] 6 6 |
70 | Other: Adalimumab treatment | [1] Adalimumab Adalimumab | [1] D02597
D02597
| [1] TNF TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 151 151 |
71 | Other: Best Medical Treatment | - | - | - | - | [1] 6 6 |
72 | Other: Control wound treatment | - | - | - | - | [1] 36 36 |
73 | Other: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet) | - | - | - | - | [1] 96 96 |
74 | Other: current treatment | - | - | - | - | [1] 46 46 |
75 | Other: Dead Sea Solar and Water Treatment | [1] Water Water | [1] D00001
D00001
| - | - | [1] 46 46 |
76 | Other: Diet treatment | - | - | - | - | [1] 240 240 |
77 | Other: Intensify treatment with the existing drug | - | - | - | - | [2] 96 96, 97 |
78 | Other: Motor Assessments before taking regular PD treatment | - | - | - | - | [1] 6 6 |
79 | Other: Motor Assessments on regular PD treatment | - | - | - | - | [1] 6 6 |
80 | Other: Multidisciplinary intensive rehabilitation treatment | - | - | - | - | [1] 6 6 |
81 | Other: No active treatment | - | - | - | - | [1] 274 274 |
82 | Other: No anti-inflammatory treatment | - | - | - | - | [1] 271 271 |
83 | Other: No IT treatment | - | - | - | - | [1] 19 19 |
84 | Other: No treatment | - | - | - | - | [2] 53 53, 274 |
85 | Other: No Treatment Arm | - | - | - | - | [1] 13 13 |
86 | Other: No treatment given | - | - | - | - | [1] 78 78 |
87 | Other: Observation of Ocrelizumab as Treatment in RRMS Patients | [1] Ocrelizumab Ocrelizumab | [1] D05218
D05218
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 13 13 |
88 | Other: On-demand treatment | - | - | - | - | [1] 299 299 |
89 | Other: Other: Symptomatic treatment of ALS | - | - | - | - | [1] 2 2 |
90 | Other: SLE treatment | - | - | - | - | [1] 49 49 |
91 | Other: Standard steroid treatment | - | - | - | - | [1] 113 113 |
92 | Other: Standard Treatment | - | - | - | - | [1] 227 227 |
93 | Other: Standard treatment according to the Clinical protocols | - | - | - | - | [3] 49 49, 51, 235 |
94 | Other: Usual drug treatment of Parkinson's disease | - | - | - | - | [1] 6 6 |
95 | Plasma from healthy young people treatment + Riluzole | [1] Riluzole Riluzole | [1] D00775
D00775
| [14] GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | [23] Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | [1] 2 2 |
96 | PPI treatment | - | - | - | - | [1] 299 299 |
97 | Prednisone and ustekinumab treatment | [2] Prednisone Prednisone, Ustekinumab | [2] D00473
D00473
,
D09214
| [4] IL12A IL12A, IL12B, IL23A, NR3C1 💬 | [29] African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | [1] 41 41 |
98 | Prednisone treatment | [1] Prednisone Prednisone | [1] D00473
D00473
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 41 41 |
99 | Probiotic treatment | - | - | - | - | [1] 294 294 |
100 | Propranolol treatment | [1] Propranolol Propranolol | [2] D00483
D00483
,
D08443
| [3] ADRB1 ADRB1, ADRB2, ADRB3 💬 | [12] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 227 227 |
101 | Regular treatment | - | - | - | - | [1] 97 97 |
102 | Repository Corticotropin Injection -Treatment Extension | [1] Corticotropin Corticotropin | [1] D00146
D00146
| [1] MC2R MC2R 💬 | [5] Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | [1] 84 84 |
103 | Routine Treatment of CD | - | - | - | - | [1] 96 96 |
104 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | [1] 65 65 |
105 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | [1] 65 65 |
106 | Simvastatin treatment for 28 days | [1] Simvastatin Simvastatin | [1] D00434
D00434
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [1] 299 299 |
107 | Standard of Care Treatment | - | - | - | - | [3] 53 53, 245, 246 |
108 | Standard Steroid Treatment | - | - | - | - | [1] 85 85 |
109 | Standard treatment with a conventional drug | - | - | - | - | [1] 13 13 |
110 | Standard-of-care treatment | - | - | - | - | [1] 49 49 |
111 | Standrd of Care treatment | - | - | - | - | [1] 64 64 |
112 | Study treatment PPI | - | - | - | - | [1] 166 166 |
113 | Surgery treatment | - | - | - | - | [1] 291 291 |
114 | Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | [3] Aldosterone Aldosterone, Angiotensin II, Calcium (Synonym: Restoration Treatment) | [3] D00150
D00150
,
D02014
,
D10528
| [3] AGTR1 AGTR1, AGTR2, NR3C2 💬 | [17] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | [1] 222 222 |
115 | Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil) | [4] Azathioprine Azathioprine, Mycophenolate mofetil, Mycophenolic acid, Tacrolimus | [8] D00107
D00107
,
D00238
,
D00752
,
D03033
,
D05094
,
D05095
,
D05096
,
D08556
| [7] IMPDH1 IMPDH1, IMPDH2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | [36] Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | [1] 11 11 |
116 | Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) | [1] Human immunoglobulin G Human immunoglobulin G | - | - | - | [1] 11 11 |
117 | Systemic non-biological treatments | - | - | - | - | [2] 46 46, 271 |
118 | The Comprehensive Treatment Regimen of Traditional Chinese Medicine | - | - | - | - | [1] 222 222 |
119 | The Standard Steroid Treatment, Plasma Exchange and rituximab | [1] Rituximab Rituximab | [1] D02994
D02994
| [1] MS4A1 MS4A1 💬 | [1] Hematopoietic cell lineage Hematopoietic cell lineage 💬 | [1] 85 85 |
120 | Time delay treatment of botulinum toxin | - | - | - | - | [1] 149 149 |
121 | TL011, anti CD20, for the treatment of rheumatoid arthritis | - | - | - | - | [1] 46 46 |
122 | Tocilizumab treatment | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 41 41 |
123 | Traditional treatment of CGD and TB | - | - | - | - | [1] 65 65 |
124 | Traditional treatments | - | - | - | - | [1] 97 97 |
125 | Transsphenoidal surgery treatment | - | - | - | - | [1] 74 74 |
126 | Treatment | - | - | - | - | [2] 41 41, 299 |
127 | Treatment A | - | - | - | - | [2] 34 34, 46 |
128 | Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status | [1] Infliximab Infliximab | [1] D02598
D02598
| [1] TNF TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 96 96 |
129 | Treatment Algorithm A | - | - | - | - | [1] 97 97 |
130 | Treatment Algorithm B | - | - | - | - | [1] 97 97 |
131 | Treatment Algorithm C | - | - | - | - | [1] 97 97 |
132 | Treatment as Usual (TAU) | - | - | - | - | [1] 85 85 |
133 | Treatment B | - | - | - | - | [2] 34 34, 46 |
134 | Treatment BX1514M | - | - | - | - | [1] 58 58 |
135 | Treatment C | - | - | - | - | [2] 34 34, 46 |
136 | Treatment D | - | - | - | - | [1] 34 34 |
137 | Treatment defined only by active substance | - | - | - | - | [1] 50 50 |
138 | Treatment I | - | - | - | - | [1] 46 46 |
139 | Treatment II | - | - | - | - | [1] 46 46 |
140 | Treatment III | - | - | - | - | [1] 46 46 |
141 | Treatment intervention | - | - | - | - | [1] 61 61 |
142 | Treatment of MTX | - | - | - | - | [1] 46 46 |
143 | Treatment of MTX and HCQ | - | - | - | - | [1] 46 46 |
144 | Treatment of MTX and TwHF | - | - | - | - | [1] 46 46 |
145 | Treatment of TCM | - | - | - | - | [1] 46 46 |
146 | Treatment of TwHF | - | - | - | - | [1] 46 46 |
147 | Treatment Phase Group 4 | - | - | - | - | [1] 113 113 |
148 | Treatment standard | - | - | - | - | [1] 61 61 |
149 | Treatment systemic therapy (prednisone) | [1] Prednisone Prednisone | [1] D00473
D00473
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 162 162 |
150 | Treatment with Adalimumab | [1] Adalimumab Adalimumab | [1] D02597
D02597
| [1] TNF TNF 💬 | [67] AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 96 96 |
151 | Treatment with azathioprin | - | - | - | - | [1] 95 95 |
152 | Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor | [4] Elexacaftor Elexacaftor, Ivacaftor, Lumacaftor, Tezacaftor | [4] D09916
D09916
,
D10134
,
D11041
,
D11507
| [1] CFTR CFTR 💬 | [8] ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | [1] 299 299 |
153 | Treatment with mycophenolat mofetil | - | - | - | - | [1] 95 95 |
154 | Treatment with polyethylene glycol (Macrogol 4000) | [1] Polyethylene glycol Polyethylene glycol | [1] D03370
D03370
| - | - | [1] 299 299 |
155 | Treatment with systemic therapy (doxycycline) | [1] Doxycycline Doxycycline | [5] D00307
D00307
,
D02129
,
D03903
,
D03904
,
D07876
| - | - | [1] 162 162 |
156 | Treatment with systemic therapy (methotrexate) | [1] Methotrexate Methotrexate | [2] D00142
D00142
,
D02115
| [2] DHFR DHFR, DHFR2 💬 | [5] Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | [1] 162 162 |
157 | Treatment with systemic therapy (prednisone) | [1] Prednisone Prednisone | [1] D00473
D00473
| [1] NR3C1 NR3C1 💬 | [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | [1] 162 162 |
158 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | [1] 162 162 |
159 | Untreated to atorvastatin treatment | [1] Atorvastatin Atorvastatin | [3] D00258
D00258
,
D00887
,
D07474
| [1] HMGCR HMGCR 💬 | [4] AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | [1] 13 13 |
160 | Usual dopaminergic per os treatment | - | - | - | - | [1] 6 6 |
161 | Vancomycin Pre-Treatment | [1] Vancomycin Vancomycin | [2] D00212
D00212
,
D00926
| - | - | [1] 97 97 |
162 | Viral load driven treatment interruption | - | - | - | - | [1] 265 265 |